The following study has recently been activated for patient enrollment by The University of Illinois Cancer Center Clinical Trials Office (CTO). Clink on the link to learn about the details regarding the study on clinicaltrials.gov.
For more information or questions about a study, email email@example.com or call 312-355-5112.
EA8143: A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Sponsor: National Cancer Institute
Collaborator: Canadian Cancer Trials Group
Principal Investigator: Daniel Moreira, MD